Fenamate NSAIDs inhibit the NLRP3 inflammasome and protect against Alzheimer’s disease in rodent models-Reference-Cited by-同舟云学术

Fenamate NSAIDs inhibit the NLRP3 inflammasome and protect against Alzheimer’s disease in rodent models

Published:2016-08-11 Issue:1 Volume:7 Page:
ISSN:2041-1723
Container-title:Nature Communications
language:en
Short-container-title:Nat Commun

Author:

Daniels Michael J. D.,Rivers-Auty Jack,Schilling Tom^ORCID,Spencer Nicholas G.,Watremez William^ORCID,Fasolino Victoria,Booth Sophie J.,White Claire S.,Baldwin Alex G.,Freeman Sally,Wong Raymond,Latta Clare,Yu Shi^ORCID,Jackson Joshua^ORCID,Fischer Nicolas,Koziel Violette,Pillot Thierry,Bagnall James,Allan Stuart M.,Paszek Pawel^ORCID,Galea James,Harte Michael K.,Eder Claudia,Lawrence Catherine B.,Brough David

Publisher

Springer Science and Business Media LLC

Subject

General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry

Link

http://www.nature.com/articles/ncomms12504.pdf

Reference49 articles.

1. Vane, J. R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat. New Biol. 231, 232–235 (1971).

2. Green, G. A. Understanding NSAIDs: From aspirin to COX-2. Clin. Cornerstone 3, 50–59 (2001).

3. Rao, P. & Knaus, E. E. Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond. J. Pharm. Pharm. Sci. 11, 81–110 (2008).

4. Weggen, S. et al. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 414, 212–216 (2001).

5. Dinarello, C. A. Biologic basis for interleukin-1 in disease. Blood 87, 2095–2147 (1996).

Cited by 353 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Potential Impact of Bioactive Compounds as NLRP3 Inflammasome Inhibitors: An Update;Current Pharmaceutical Biotechnology;2024-10

2. Transient receptor potential channels as an emerging target for the treatment of Alzheimer's disease: Unravelling the potential of pharmacological interventions;Basic & Clinical Pharmacology & Toxicology;2024-08-29

3. Chloranthalactone B covalently binds to the NACHT domain of NLRP3 to attenuate NLRP3-driven inflammation;Biochemical Pharmacology;2024-08

4. Targeting NLRP3 Inflammasomes: A Trojan Horse Strategy for Intervention in Neurological Disorders;Molecular Neurobiology;2024-07-23

5. Targeting Microglia in Alzheimer’s Disease: Pathogenesis and Potential Therapeutic Strategies;Biomolecules;2024-07-11